# ALPHA-SYNUCLEIN E46K Research Report **Protein:** ALPHA-SYNUCLEIN E46K **Variant:** E46K **UniProt ID:** P37840 **Disease Association:** Parkinson's disease **Report Generated:** 2026-07-26 17:09 UTC **AlphaFold Confidence (pLDDT):** 59.7% **Structure Folded:** 2026-06-19 --- ## Structure Summary Alpha-synuclein is a protein that forms toxic clumps in the brains of people with Parkinson's disease, and the E46K mutation is a rare genetic change that causes an inherited form of this disease. Scientists used computer modeling to predict the three-dimensional structure of this mutant protein, but the analysis produced low confidence scores (average 59.7 out of 100), indicating the protein likely lacks stable structure. This finding aligns with what researchers know about alpha-synuclein: it's an intrinsically disordered protein that only adopts defined shapes when it clumps together, making it challenging to study but critical to understanding Parkinson's disease. --- Alpha-synuclein is a small neuronal protein that plays a central role in Parkinson's disease (PD) pathology. When this protein misfolds and aggregates into clumps called Lewy bodies, it contributes to the death of dopaminergic neurons in the substantia nigra region of the brain, causing the characteristic motor symptoms of PD [1][3]. The E46K mutation (where glutamic acid at position 46 is replaced by lysine) is one of several rare genetic variants that cause familial, early-onset Parkinson's disease, demonstrating that even single amino acid changes can dramatically increase the protein's tendency to form toxic aggregates. The structural prediction of E46K alpha-synuclein using AlphaFold2 yielded an average confidence score (pLDDT) of 59.7, which falls well below the threshold of 70 typically considered reliable for structural interpretation. This low confidence does not represent a failure of the prediction method, but rather reflects an inherent property of alpha-synuclein itself: it is an intrinsically disordered protein that lacks a stable three-dimensional structure in its soluble, monomeric form. The prediction uncertainty is highest because alpha-synuclein exists as a flexible, unfolded chain under normal conditions and only adopts defined conformations when bound to membranes or when aggregating into pathological fibrils [2]. The E46K mutation, which replaces a negatively charged residue with a positively charged one, likely alters the protein's electrostatic properties and increases its propensity to self-associate. Recent research has provided critical insights into how alpha-synuclein aggregation drives neurodegeneration in Parkinson's disease. Studies using preformed fibrils (PFFs) demonstrate that aggregated alpha-synuclein can seed the misfolding of normal protein, creating a self-propagating cascade of pathology [6]. The fragmentation and reaggregation of these fibrils appears to be a key mechanism for spreading pathology, with fibril breakage generating new seeds that can nucleate additional aggregation [2]. This prion-like spreading mechanism may explain how Parkinson's pathology progressively affects different brain regions over time. Cellular models have shown that genetic disruptions affecting lysosomal degradation pathways can exacerbate alpha-synuclein accumulation, suggesting that impaired protein clearance contributes to disease progression [3][5]. The E46K mutation is clinically significant as one of the confirmed genetic causes of autosomal dominant Parkinson's disease, meaning that inheriting just one copy of the mutated gene is sufficient to cause disease. Families carrying this mutation typically develop Parkinson's symptoms at earlier ages than sporadic cases. While the low structural confidence prevents detailed atomic-level analysis of how E46K specifically alters protein folding, the charge reversal at position 46 (from negative to positive) almost certainly affects the protein's aggregation kinetics and may accelerate fibril formation. Understanding these familial mutations remains crucial because they provide definitive proof that alpha-synuclein dysfunction directly causes Parkinson's disease, validating it as a therapeutic target [4][7]. ## Works Cited [1] Wang et al. (2026). Loss-of-Function (G603R) Lrp10 Fails to Downregulate mRNA of Pathologic alpha-Synuclein and Causes Neurodegeneration of Substantia Nigra Dopaminergic Cells in Parkinson's Disease Knockin Mice. Neurochemical research. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42159631/) [2] Havemeister et al. (2026). Fragmentation-Induced Disassembly and Reaggregation of alpha-Synuclein Amyloid Fibrils. ACS chemical neuroscience. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42159605/) [3] Wang et al. (2026). Lrp10 insufficiency upregulates mRNA and protein of neurotoxic alpha-synuclein and causes degeneration of substantia nigra dopaminergic neurons in heterozygous or homozygous Lrp10 knockout mice. Neurochemistry international. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42142532/) [4] Latimer et al. (2026). Heterogenous Neuropathology in a Pedigree with RAB39B-Related Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42138034/) [5] Scholz et al. (2026). Knockout of Rab27b exacerbates neuropathology in alpha-synuclein mouse models. Acta neuropathologica communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42121002/) [6] Han et al. (2026). An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neurons. Methods (San Diego, Calif.). [PubMed](https://pubmed.ncbi.nlm.nih.gov/42297199/) [7] Ibarra-Aizpurua et al. (2026). Reactive astrocytes mediate toxicity in iPSC derived dopaminergic neurons. NPJ Parkinson's disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42285981/) ## Similar Research **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase.** Fiesel et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40624741/) **Synergism of IP3R and Parkin mutants identifies mitochondrial stress as an early feature of Parkinson's disease.** Dileep et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41235839/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease.** Menozzi et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41569009/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | Hereditary late-onset Parkinson disease | 0.788 | literature, genetic_association, genetic_literature | | Young adult-onset Parkinsonism | 0.773 | literature, genetic_association, genetic_literature | | Lewy body dementia | 0.742 | literature, animal_model, genetic_association, genetic_literature | | Parkinson disease | 0.711 | rna_expression, genetic_literature, clinical, literature, genetic_association | | AL amyloidosis | 0.462 | affected_pathway | | insomnia | 0.385 | literature, genetic_association | | REM sleep behavior disorder | 0.381 | literature, genetic_association | | parkinsonian-pyramidal syndrome | 0.370 | genetic_association | | Abnormality of the skeletal system | 0.336 | genetic_association | | Anxiety | 0.323 | literature, genetic_association | *...and 791 more associations* --- ## Agent Findings ### Literature (1) - **2026-06-20:** None of the provided papers directly examine the E46K variant of alpha-synuclein. While several papers investigate other alpha-synuclein variants (A30P in PMIDs 41856188, 41990982; A53T in PMIDs 41831819, 42074567) and general alpha-synuclein biology relevant to Parkinson's disease pathogenesis, the specific E46K mutation that was requested is not addressed in this collection. ### Clinical (1) - **2026-06-20:** ### Structural (1) - **2026-06-20:** AlphaFold structure update: Baseline check: 3 structure(s) found ### Synthesis (1) - **2026-06-20:** Synthesis of 1 findings (peptides): Synthesis JSON could not be parsed; raw response is in agent logs.... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)